Complement Therapeutics joins SBC as the company secures Series A funding

We are thrilled to welcome to a new tenant on the SBC campus, Complement Therapeutics.

Complement Therapeutics is a German headquartered early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The company's move to SBC coincides with the announcement it has secured €72 million in Series A funding.

We are delighted that Complement Therapeutics has joined our world-class cluster of excellence which accelerates the translation of cutting-edge science to improve people's health and the quality of their lives. The SBC ecosystem brings together academics, biotech and pharma organisations in the spirit of collaboration and partnership. This has been achieved by providing access to networks, support and expertise to enable them to connect, grow and succeed in the development and commercialisation of life changing therapies.

We wish the team continued success. 

Find out more about the Complement Therapeutics here.